SCHEMBL5638490

SCHEMBL5638490

Nc1ccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCCO3)c(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.56
HTR2A P28223 2/20 0.56
HTR2B P41595 2/20 0.56
GLA P06280 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
TLR8 Q9NR97 3/20 0.32
TLR7 Q9NYK1 1/20 0.32
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637064 0.90 HTR2C (0.56) HTR2CHTR2AHTR2BTLR8TLR7
SCHEMBL5637170 0.88 HTR2C (0.54) HTR2CHTR2AHTR2B
SCHEMBL5637201 0.87 HTR2C (0.56) HTR2CHTR2AHTR2BTLR8TLR7
SCHEMBL5636468 0.87 HTR2C (0.75) HTR2CHTR2AHTR2B
SCHEMBL5635151 0.85 HTR2A (0.62) HTR2CHTR2AHTR2B
SCHEMBL17039082 0.85 HTR2C (0.54) HTR2CHTR2AHTR2B
SCHEMBL5636371 0.85 HTR2C (0.62) HTR2CHTR2AHTR2B
SCHEMBL15800579 0.85 HTR2C (0.62) HTR2CHTR2AHTR2B
SCHEMBL5637734 0.85 HTR2C (0.54) HTR2CHTR2AHTR2BGAATLR8
SCHEMBL6916999 0.85 HTR2C (0.76) HTR2CHTR2AHTR2BGLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed